Research programme: eptacog alfa inhalation - Savara Pharmaceuticals

Drug Profile

Research programme: eptacog alfa inhalation - Savara Pharmaceuticals

Alternative Names: Recombinant FVIIa inhalation - Serendex; Recombinant human factor VIIa inhalation - Serendex; rhFVIIa inhalation - Serendex

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CMC Biologics
  • Developer Serendex Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor IX stimulants; Factor X stimulants; Haemostasis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemorrhage

Most Recent Events

  • 18 Jul 2016 Serendex Pharmaceuticals has been acquired and merged into Savara Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for research development in Haemorrhage in Denmark (Inhalation, Inhalant)
  • 21 Jun 2016 Savara Pharmaceuticals acquires eptacog alfa inhalation from Serendex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top